Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$69.5MCash on Hand
57.9mo Cash Runway
Follow KZIA by emailGet an email when KZIA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KZIA, unsubscribe in one click. Privacy
📣 What KZIA Says Is Next
in 2028 · “Clinical updates are anticipated throughout 2027, with a full readout anticipated in 2028.”
Company press release, Sep 1, 2026 · SEC filing
the end of 2026 · “The Company expects sites for this expansion to be activated and the first patient enrolled before the end of 2026, with full enrollment anticipated by the end of 2027.”
Company press release, Sep 1, 2026 · SEC filing
this year · “This gives us the opportunity to enrich for the patients where this biology matters most and brings precision medicine to HR+ breast cancer.” This benchmarking work is ongoing, and Kazia expects to present additional data later this year, including further cellular, molecular and epigenetic characterization of paxalisib relative to other PI3K/mTOR inhibitors.”
Company press release, Sep 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Sep 22, 2026 ·
Deal Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for focal cortical dysplasia type 2 and tuberous sclerosis complex, triggering a $2 million development milestone payment to Kazia. Kazia can receive up to $17 million more in milestones plus royalties. Form 6-K · SEC filing · Press release
Sep 22, 2026 ·
Clinical trial Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for focal cortical dysplasia type 2 and tuberous sclerosis complex, triggering a $2 million development milestone payment to Kazia under their March 2024 license. Kazia may receive up to $17 million more in milestones. Form 424B3 · SEC filing
Sep 22, 2026 ·
Deal Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for focal cortical dysplasia type 2 and tuberous sclerosis complex, triggering a $2 million development milestone payment to Kazia. Up to $17 million in further milestones are possible under the license. Form 424B3 · SEC filing
Sep 22, 2026 ·
Deal Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for focal cortical dysplasia type 2 and tuberous sclerosis complex, triggering a $2 million milestone payment to Kazia under their March 2024 license. Kazia is eligible for up to $17 million more in milestones. Form 424B3 · SEC filing
Sep 22, 2026 ·
Deal Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for intractable epilepsy linked to FCD T2 and TSC, triggering a $2 million development milestone payment to Kazia. Kazia is also eligible for up to $17 million in further milestones. Form 424B3 · SEC filing
Sep 18, 2026 ·
Listing Kazia Therapeutics appointed JPMorgan Chase Bank, N.A. as sole depositary for its ADR program, replacing BNY Mellon. ADSs will each represent 500 ordinary shares and continue to trade on Nasdaq under KZIA, and holders need take no action. Form 6-K · SEC filing
Sep 18, 2026 ·
Kazia appointed JPMorgan Chase Bank, N.A. as sole depositary for its ADR program, replacing BNY Mellon, under a Second Amended and Restated Deposit Agreement. Each ADS will represent 500 ordinary shares and continue trading as KZIA on Nasdaq. ADS holders need take no action. Form 424B3 · SEC filing
Sep 18, 2026 ·
Kazia appointed JPMorgan Chase Bank, N.A. as sole depositary for its ADR program, replacing The Bank of New York Mellon. ADSs will represent 500 ordinary shares and keep trading on Nasdaq as KZIA, and holders need take no action. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2024 · Phase 1 · Results Expected · Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours Registry primary completion date, not a results date
Mar 2023 · Phase 1 · Results Expected · Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects Registry primary completion date, not a results date
Mar 2023 · Phase 2 · Results Expected · Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma Registry primary completion date, not a results date
Mar 2020 · Phase 1 · Results Expected · Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not KZIA's own candidates): Lomustine, Temozolomide, Regorafenib, Abemaciclib, Trastuzumab, Nivolumab And Relatlimab-Rmbw, Entrectinib, Adagrasib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
KZIA holds $69.5M in cash and short-term investments and burns about $3.6M/quarter from operations,
an estimated runway of 57.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:35 · Moderate
Cash runway 58 months
ATM program on file since Aug 2026 +15
Shelf registration (F-3, Mar 2026) +10
Share count +143% in a year +20
Raised after last reported balance sheet (Aug 2026) -10
Share count 809,418,734 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full KZIA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KZIA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.